| Title: |
A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models. |
| Authors: |
White, Michael J., Cheatham, Letitia, Wen, Shenghua, Scarfe, Graeme, Cidado, Justin, Reimer, Corinne, Hariparsad, Niresh, Jones, Rhys D. O., Drew, Lisa, McGinnity, Dermot F., Vasalou, Christina |
| Source: |
AAPS Journal; Jul2023, Vol. 25 Issue 4, p1-8, 8p |
| Abstract: |
Capturing human equivalent drug exposures preclinically is a key challenge in the translational process. Motivated by the need to recapitulate the pharmacokinetic (PK) profile of the clinical stage Mcl-1 inhibitor AZD5991 in mice, we describe the methodology used to develop a refined mathematical model relating clinically relevant concentration profiles to efficacy. Administration routes were explored to achieve target exposures matching the clinical exposure of AZD5991. Intravenous infusion using vascular access button (VAB) technology was found to best reproduce clinical target exposures of AZD5991 in mice. Exposure-efficacy relationships were evaluated, demonstrating that dissimilar PK profiles result in differences in target engagement and efficacy outcomes. Thus, these data underscore the importance of accurately ascribing key PK metrics in the translational process to enable clinically meaningful predictions of efficacy. [ABSTRACT FROM AUTHOR] |
|
Copyright of AAPS Journal is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
Full Text from SpringerLink